CREST Physician Experience Survey: Evaluating the Impact of Time and Effort of Treatment Administration in Non-Muscle Invasive Bladder Cancer (NMIBC)
Author(s)
Anthony Eccleston, MSc1, Leo Chen, MPH2, Joe Brown, BSc3, Julia Brinkmann, MD, MBA4, Sanjana Chandrasekar, MPH5, Jane Chang, MPH2.
1Pfizer Inc, Surrey, United Kingdom, 2Pfizer Inc, New York, NY, USA, 3Icon PLC, Blue Bell, PA, USA, 4Pfizer Pharma GmbH, Berlin, Germany, 5Pfizer, New York, NY, USA.
1Pfizer Inc, Surrey, United Kingdom, 2Pfizer Inc, New York, NY, USA, 3Icon PLC, Blue Bell, PA, USA, 4Pfizer Pharma GmbH, Berlin, Germany, 5Pfizer, New York, NY, USA.
OBJECTIVES: Standard of care for high-risk (HR)-NMIBC is transurethral resection of the bladder tumor followed by intravesical Bacillus Calmette-Guerin (BCG) induction and maintenance. Approximately 40% of patients experience disease progression or recurrence at 24 months, with unfavorable prognosis and limited treatment options. Sasanlimab, a new subcutaneous (SC) programmed cell death protein 1 (PD-1) inhibitor, with BCG is in development for the treatment of BCG-naive HR-NMIBC (CREST trial, NCT04165317). We surveyed investigators from CREST to better understand the time and effort required, specifically regarding the setting and healthcare professional involvement, for the treatment of HR-NMIBC with BCG and either SC sasanlimab or an intravenous (IV) PD-(L)1 inhibitor from any other clinical trial.
METHODS: Five 60-minute cognitive interviews were conducted to help develop survey questions. The 23-item online survey, which included questions regarding diagnosis and treatment selection/management, was provided to active investigators in 6 languages.
RESULTS: Globally, 25 investigators (20 urologists and 5 oncologists) participated in the survey; of these, 16 had experience with IV therapy. Urologists primarily led patient diagnosis (93%) and treatment selection (81%). Urologists (68%) and urology nurses (26%) are expected to manage and treat NMIBC in the real-world. Overall, 52% of respondents reported sasanlimab plus BCG required little-to-no effort to schedule a patient compared with 13% of respondents for IV combination therapy. In clinical trial settings, total administration time (including preparation, administration, monitoring, and waiting times) was 70 minutes with SC sasanlimab and 136 minutes with IV PD-(L)1 inhibitor therapy; 48% of respondents believed sasanlimab would have quicker administration in real-world settings vs 44% for IV PD-(L)1 inhibitor therapy.
CONCLUSIONS: Despite small sample, findings suggest that among specialists, urologists lead diagnosis and treatment selection in HR-NIMBC. Pending approval, SC sasanlimab may offer a quicker, more convenient treatment option, potentially saving time, effort, and resource costs for healthcare systems.
METHODS: Five 60-minute cognitive interviews were conducted to help develop survey questions. The 23-item online survey, which included questions regarding diagnosis and treatment selection/management, was provided to active investigators in 6 languages.
RESULTS: Globally, 25 investigators (20 urologists and 5 oncologists) participated in the survey; of these, 16 had experience with IV therapy. Urologists primarily led patient diagnosis (93%) and treatment selection (81%). Urologists (68%) and urology nurses (26%) are expected to manage and treat NMIBC in the real-world. Overall, 52% of respondents reported sasanlimab plus BCG required little-to-no effort to schedule a patient compared with 13% of respondents for IV combination therapy. In clinical trial settings, total administration time (including preparation, administration, monitoring, and waiting times) was 70 minutes with SC sasanlimab and 136 minutes with IV PD-(L)1 inhibitor therapy; 48% of respondents believed sasanlimab would have quicker administration in real-world settings vs 44% for IV PD-(L)1 inhibitor therapy.
CONCLUSIONS: Despite small sample, findings suggest that among specialists, urologists lead diagnosis and treatment selection in HR-NIMBC. Pending approval, SC sasanlimab may offer a quicker, more convenient treatment option, potentially saving time, effort, and resource costs for healthcare systems.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HSD29
Topic
Health Service Delivery & Process of Care
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology